Determination of drug-metabolizing enzyme activity in vivo: Pharmacokinetic and statistical issues

Xenobiotica

Volumn 28, Issue 12, 1998, Pages 1255-1273

  Tucker, G T ^a   Rostami Hodjegan, A ^a   Jackson, P R ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450; DNA; DRUG METABOLIZING ENZYME; METHYLXANTHINE;

AREA UNDER THE CURVE; ARTICLE; COMPUTER SIMULATION; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; GENE LOCUS; GENOTYPE; HERITABILITY; HUMAN; KIDNEY CLEARANCE; NONHUMAN; PHENOTYPE; STATISTICAL ANALYSIS;

AREA UNDER CURVE; CAFFEINE; CYTOCHROME P-450 ENZYME SYSTEM; GENETICS, POPULATION; HUMANS; METABOLIC DETOXICATION, DRUG; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS; POLYMORPHISM, GENETIC; REPRODUCIBILITY OF RESULTS; VARIATION (GENETICS);

EID: 0032426427     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598238895     Document Type: Article

References (57)

1. BARTSCH, H., CAPORASO, N., CODA, M., KADLUBAR, F., MALAVEILLE, C., SKIPPER, P., TALASKA, G., TANNENBAUM, S. R. and VINEIS, P., 1990, Carcinogen hemoglobin adducts, urinary mutagenicity and metabolic phenotype in active and passive cigarette smokers. Journal of the National Cancer Institute, 82, 1826-1831.
2. BAX, N. D. S., LENNARD, M. S. and TUCKER, G. T., 1981, Inhibition of antipyrine metabolism by beta-adrenergic antagonists. British Journal of Clinical Pharmacology, 12, 779-784.
3. BERTILLSON, L., LOU, Y. Q., DU, Y. L., LIU, Y., LIAO, X. M., WANG, K. Y., REVIRIEGO, J., ISELIUS, L. and SJOQVIST, F., 1992, Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clinical Pharmacology and Therapeutics, 51, 388-397.
4. BIRKETT, D. J., MINERS, J. O. and DAY, R. O., 1991, 1-Methylxanthine derived from theophylline as an indirect in vivo biochemical probe of allopurinol effect. British Journal of Clinical Pharmacology, 32, 238-241.
5. BRANCH, R. A. and SHAND, D. G., 1979, A re-evaluation of intersubject variation in enzyme induction in man. Clinical Pharmacokinetics, 4, 104-110.
6. BUTLER, M. A., LANG, N. P., YOUNG, J. F., CAPAROSO, N. E., VINEIS, P., HAYES, R. B., TEITEL, C. H., MASSENGILL, J. P., LAWSEN, M. F. and KADLUBAR, F. F., 1992, Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2, 116-127.
7. CAMPBELL, M. E., SPIELBERG, S. P. and KALOW, W. A., 1987, A urinary metabolite ratio that reflects systemic caffeine clearance. Clinical Pharmacology and Therapeutics, 42, 157-165.
8. CARRILLO, J. A. and BENITE, J., 1994, Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clinical Pharmacology and Therapeutics, 55, 293-334.
9. DAHL, M.-L., JOHANSSON, I., BERTILSSON, L., INGELMAN-SUNDBERG, M. and SJOQVIST, F., 1995, Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. Journal of Pharmacology and Experimental Therapeutics, 274, 516-520.
10. DAVIDIAN, M. and GALLANT, A. R., 1992, Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine. Journal of Pharmacokinetics and Biopharmaceutics, 20, 529-556.
11. EFRON, B. and GONG, G., 1983, A leisurely look at the bootstrap, the jackknife and cross-validation. American Statistician, 37, 36-48.
12. ENDRENYI, L. and PATEL, M. 1991, A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot. British Journal of Clinical Pharmacology, 32, 159-166.
13. EVERITT, B. S. and HAND, D. J., 1981, Finite Mixture Distributions (London: Chapman & Hall).
14. FUHR, U. and ROST, K. L., 1994, Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics, 4, 109-116.
15. GHAHRAMANI, P., ELLIS, S. W., LENNARD, M. S., RAMSAY, L. E. and TUCKER, G. T., 1997, Cytochromes P450 mediating the N-demethylation of amitriptyline. British Journal of Clinical Pharmacology, 43, 137-144.
16. GRANT, D. M., TANG, B.-K. and KALOW, W. A. 1983a, Variability in caffeine metabolism. Clinical Pharmacology and Therapeutics, 33, 591-602.
17. GRANT, D. M., TANG, B.-K. and KALOW, W. A., 1983b, Polymorphic N-acetylation of caffeine metabolite. Clinical Pharmacology and Therapeutics, 33, 355-359.
18. HUSSEIN, Z., EAVES, C. J., HUTCHINSON, D. B, and CANFIELD C. J., 1996, Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. British Journal of Clinical Pharmacology, 42, 589-597.
19. JACKSON, P. R., 1987, Theoretical and experimental studies of variability in drug disposition. PhD thesis, University of Sheffield.
20. JACKSON, P. R. and TUCKER, G. T., 1990, Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphisms in xenobiotic metabolism. Annals of Occupational Hygiene, 34, 653-662.
21. JACKSON, P. R., TUCKER, G. T., LENNARD, M. S. and WOODS, H. F., 1986, Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. British Journal of Clinical Pharmacology, 22, 541-550.
22. JACKSON, P. R., TUCKER, G. T., LENNARD, M. S. and WOODS, H. F., 1990, Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism - statistical methods. In P. Alvan, L. P. Balant, P. R. Bechtel, A. R. Boobis, L. F. Gram and P. Pithan (eds), European Consensus Conference on Pharmacogenetics (Brussels: Commission of the European Communities), pp. 43-52.
23. JACKSON, P. R., TUCKER, G. T. and WOODS, H. F., 1989a, Testing for bimodality in frequency distributions of data suggesting polymorphism of drug metabolism - histograms and probit plots. British Journal of Clinical Pharmacology, 28, 647-653.
24. JACKSON, P. R., TUCKER, G. T. and WOODS, H. F., 1989b, Testing for bimodality in frequency distributions of data suggesting polymorphism of drug metabolism - hypothesis testing. British Journal of Clinical Pharmacology, 28, 655-662.
25. JEFFREYS, A. J., 1979, DNA sequence variants in the G gamma-, A gamma, delta- and beta-globin genes of man. Cell, 18, 1-10.
26. JOHANSSON, I., OSCARSON, M., YUE, Q. Y., BERTILLSON, L., SJOQVIST, F. and INGELMAN-SUNDBERG, M., 1994, Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Molecular Pharmacology, 46, 452-459.
27. KADLUBAR, F. F., 1994, Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metabolism Reviews, 26, 37-46.
28. KADLUBAR, F. F., TALASKA, G., BUTLER, M. A., TEITEL, C. H., MASSENG, J. P. and LANG, N. P., 1990, Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites. Progress in Clinical and Biological Research, 340B, 107-114.
29. KALOW, W. and TANG, B.-K., 1991a, Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clinical Pharmacology and Therapeutics, 49, 444-48.
30. KALOW, W. and TANG, B.-K., 1991b, Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clinical Pharmacology and Therapeutics, 50, 508-519.
31. KALOW, W. and TANG, B.-K., 1993, The use of caffeine for enzyme assays: a critical appraisal. Clinical Pharmacology and Therapeutics, 53, 503-514.
32. MACLEAN, C. J., MORTON, N. E., ELSTON, R. C. and YEE, S., 1976, Skewness in commingled distributions. Biometrics, 32, 695-699.
33. MALLET, A., MENTRE, F., STEIMER, J. L. and LOKIEC, F., 1988, Nonparametric maximum likelihood estimation for population pharmacokinetics, with application to cyclosporine. Journal of Pharmacokinetics and Biopharmaceutics, 16, 311-327.
34. MEISEL, P., SCHROEDER, C., WULFF, K. and SIEGMUND, W., 1997, Relationship between human genotype and phenotype of N-acetyltransferase (NAT2) as estimated by discriminant analysis and multiple linear regression: 1. Genotype and N-acetylation in vivo. Pharmacogenetics, 7, 241-246.
35. MILLER, C. A., SLUSHER, L. B. and VESELL, E. S., 1985, Polymorphism of theophylline metabolism in man. Journal of Clinical Investigation, 75, 1415-1425.
36. MURPHY, E. A., 1964, One cause? Many causes? The argument from the bimodal distribution. Journal of Chronic Diseases, 17, 301-324.
37. NAKAJIMA, M., YOKOI, T., MIZUTANI, M., SHIN, S., KADLUBAR, F. F. and KAMATAKI, T., 1994, Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiological Markers Reviews, 3, 413-421.
38. NOTARIANNI, L. J., OLIVER, S. E., DOBROCKY, P., BENNETT, P. N. and SILVERMAN, B. W., 1995, Caffeine as a metabolic probe: A comparison of the metabolic ratios used to assess CYP1A2 activity. British Journal of Clinical Pharmacology, 39, 65-69.
39. PEARSON, K., 1900, On a criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have risen from random sampling. Philosophical Magazine, 5th series, 50, 157-172.
40. PENNO, M. B. and VESELL, E. S., 1983, Monogenetic control of variations in antipyrine metabolite formation. Journal of Clinical Investigation, 71, 1698-1709.
41. PIOTROVSKIJ, V. and VAN PEER, A., 1997, A model with separate hepato-portal compartment ('first-pass' model): fitting to plasma concentration-time profiles in humans. Pharmaceutical Research, 14, 230-237.
42. RELLING, M. V., LIN, J.-S., AYERS, G. D. and EVANS, W. E., 1992, Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clinical Pharmacology and Therapeutics, 52, 643-658.
43. RIEDER, M. J., SHEAR, N. H., KANEE, A., TANG, B.-K. and SPIELBERG, S. P., 1991, Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reaction. Clinical Pharmacology and Therapeutics, 49, 13-17.
44. ROEDER, K., 1994, A graphical technique for determining the number of components in a mixture of normals. Journal of the American Statistical Association, 89, 487-495.
45. ROSE, K. L. and ROOTS, I., 1994, Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolic ratios: coincidence with plasma clearance and breath test. Clinical Pharmacology and Therapeutics, 55, 402-411.
46. ROSTAMI-HODJEGAN, A., NURMINEN, S., JACKSON, P. R. and TUCKER, G. T., 1996, Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 6, 121-149.
47. SACHSE, C., BROKMOLLER, J., BAUER, S. and ROOTS, I., 1997, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. American Journal of Human Genetics, 60, 284-295.
48. SHEINER, L. B., ROSENBERG, B. and MARATHE, V. V., 1977, Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5, 445-479.
49. SILVERMAN, B. W., 1981, Using kernel density estimates to investigate multimodality. Journal of the Royal Statistical Society, 43, 97-99.
50. TANAKA, E., ISHIKAWA, A., YAMAMOTO, Y., OSADA, A., TSUJI, K. and FUKAO, K., 1992, A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. International Journal of Clinical Pharmacology, Therapeutics and Toxicology, 30, 336-341.
51. TANG, B.-K., KADAR, D., QIAN, L., IRIAH, J., YIP, J. and KALOW, W., 1991, Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clinical Pharmacology and Therapeutics, 49, 648-657.
52. TANG, B.-K., ZHOU, Y., KADAR, D. and KALOW, W., 1994, Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics, 4, 117-124.
53. TRANSON, C., LECOEUR, S., LEEMANN, T., BEAUNE, P. and DAYER, P., 1996, Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. European Journal of Clinical Pharmacology, 51, 79-85.
54. TUCKER, G. T., JACKSON, P. R., LENNARD, M. S. and WOODS, H. F., 1989, Pharmacokinetic-pharmacogenetic modelling-a basis for the display and detection of polymorphisms in xenobiotic metabolism. In P. Alvan, L. P. Balant, P. R. Bechtel, A. R. Boobis, L. F. Gram and K. Pithan (eds), European Consensus Conference on Pharmacogenetics (Brussels: Commission of the European Communities), pp. 59-67.
55. VESELL, E. S. and GAYLOR, D. W., 1995, Limitations of probit plots in pharmacogenetics: requirement of genetic analysis to test hypotheses based on graphical methods. Pharmacogenetics, 5, 18-23.
56. VISTISEN, K., POULSEN, H. E. and LOFT, S., 1992, Foreign compound metabolism in man measured from metabolites of dietary caffeine. Carcinogenesis, 13, 1561-1568.
57. WILKINSON, G. R. and SHAND, D. G., 1975, A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics, 18, 377-390.